BriaCell Highlights Blood Biomarker Linked to Breast Cancer Outcomes at ESMO 2026

Key Points

• A pooled analysis of 111 patients with metastatic breast cancer found that an immune marker measured after treatment was associated with clinical outcomes.
• At approximately three months, PD-L1 levels on circulating cancer-associated macrophage-like cells were significantly associated with both progression-free and overall survival.
• The analysis combined patients from several studies and treatments, including BriaCell’s earlier Bria-IMT trial. It does not establish a benefit specific to Bria-IMT.
• Further research is needed before the marker can be validated for predicting treatment response.
• BriaCell’s separate pivotal Phase 3 trial remains ongoing.

BriaCell Therapeutics (NASDAQ: BCTX) recently presented findings at ESMO 2026 suggesting that a blood-based biomarker could help researchers understand how patients with metastatic breast cancer respond to immunotherapy.

The analysis examined PD-L1 expression on circulating cancer-associated macrophage-like cells, or CAMLs. Its central finding was that measurements taken after treatment began were associated with outcomes, while the pretreatment measurement was not.

Follow-Up Measurements Showed Stronger Links to Survival

Researchers collected blood before treatment, approximately 37 days after treatment began and again at around three months.

At 37 days, CAML PD-L1 was significantly associated with progression-free survival—the time patients lived without their cancer worsening—but not overall survival.

At approximately three months, it was significantly associated with both measures. The reported hazard ratios were 2.73 for progression-free survival and 2.27 for overall survival. However, the announcement does not clearly identify the comparison groups behind those ratios, so they should not be interpreted as a percentage improvement in survival.

The findings support studying whether repeated measurements offer useful information beyond a single pretreatment test.

Pooled Results Are Not a Standalone Test of Bria-IMT

The analysis included 111 patients who received different immune checkpoint inhibitors, with some also receiving the Bria-IMT regimen. Patients had received a median of two prior treatment lines for metastatic disease, and 60% had triple-negative breast cancer.

Because the data combine multiple studies and treatment regimens, they do not isolate Bria-IMT’s effectiveness. An association with survival also does not establish that the marker can reliably identify which treatment will benefit an individual patient.

Phase 3 Survival Trial Remains the Key Clinical Milestone

BriaCell’s ongoing pivotal trial compares Bria-IMT plus an immune checkpoint inhibitor with physician’s choice treatment. Overall survival is the primary endpoint.

A planned interim analysis will occur after 144 patient deaths. The announcement does not provide a date for that analysis or new Phase 3 results.

Investor Takeaway: Biomarker Research Adds Context, Not Proof of Treatment Benefit

For BCTX investors, the poster adds a potential way to study treatment response through blood monitoring.

The more consequential milestone remains the randomized Phase 3 survival results. This biomarker analysis does not establish Bria-IMT’s efficacy, validate a clinical decision-making test or represent a regulatory approval.